IntegenX

Pleasanton, United States Founded: 2006 • Age: 20 yrs Acquired By Thermo Fisher Scientific
Instruments for rapid human DNA identification are developed.

About IntegenX

IntegenX is a Healthcare company based in Pleasanton (United States) founded in 2006, and was acquired by Thermo Fisher Scientific in March 2018. Instruments for rapid human DNA identification are developed. IntegenX has raised $92.06 million across 9 funding rounds from investors including Thermo Fisher Scientific, Square 1 Bank and HHS. The company has 78 employees. IntegenX has completed 1 acquisition, including GenVault Corporation. The company was acqui-hired. IntegenX offers products and services including RapidHIT ID System and TaqMan Real-Time PCR Assays. Its focus areas include Life Sciences, Genomics, Applied Genomics and Other Applications. Its legal entity is Thermo Fisher Scientific Inc. Its competitors include DDC Paternity Tests, Othram and ANDE; 2 of its 3 listed competitors have raised funding.

Company details

Founded in 2006 and based in Pleasanton, United States, IntegenX operates in the forensics and law enforcement sector. Advanced fluidics, optics, and biochemistry are integrated into its proprietary platforms to create sample-to-answer products for DNA-based identity testing. As of January 2016, the RapidHIT ID and RapidHIT System, along with supporting reagent kits, are offered for these applications.

Key Metrics
  • Annual Revenue
    $22.5 B (USD)
    14513
    as on Dec 31, 2024
  • Net Profit
    $6.34 B (USD)
    6
    as on Dec 31, 2024
  • EBITDA
    $1.96 B (USD)
    2
    as on Dec 31, 2024
  • Total Equity Funding
    $92.06M (USD)

    in 9 rounds

  • Latest Funding Round
    $10M (USD), Debt – Venture

    Sep 2014

  • Investors
  • Employee Count
    78
  • Investments & Acquisitions
  • Acquired by

Products & Services of IntegenX

IntegenX offers a comprehensive portfolio of products and services, including RapidHIT ID System and TaqMan Real-Time PCR Assays.

RapidHIT ID System
Forensic DNA Analysis

Compact system for generating DNA profiles in forensic settings

TaqMan Real-Time PCR Assays
Molecular Testing

Assays for DNA analysis in various scientific applications

Funding Insights of IntegenX

IntegenX has successfully raised a total of $92.06M across 9 strategic funding rounds. The most recent funding activity was a Debt – Venture round of $10 million completed in September 2014. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

  • Total Funding $92.06M
  • Total Rounds 9
  • Last Round Debt – Venture β€” $10M
  • First Round $4.5M

    (Aug 2006)

  • Investors Count 12

All 9 funding rounds of IntegenX with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.

DateAmountTransaction NameValuationLead InvestorsInvestors
Sep 2014$10MDebt – Venture––
Dec 2012$48.84MSeries C–EW Healthcare Partners
Dec 2011$5MDebt – Conventional––
Jan 2011$20.62MSeries B––
Nov 2009$18.1MSeries B––
Sep 2009$843,715Grant––
May 2007$843,715Grant––
Sep 2006$843,715Grant––
Aug 2006$4.5MSeries A––
Valuation history

13 investors in total: 13 institutional.

Investors in IntegenX

IntegenX has secured backing from 13 investors, including venture fund and institutional investors. Prominent investors backing the company include Thermo Fisher Scientific, Square 1 Bank and HHS.

All
Venture Fund
Institutional
InvestorDescriptionFounded YearDomainLocation
Structured debt is provided to life sciences and technology firms.
2004horizontechfinance.comFarmington, United States
Life science & tech focused VC firm investing in the US
domainvc.comPrinceton, United States
Expansion stage tech-focused VC firm investing primarily in the US
questm.comBaltimore, United States
Diversified investment management firm
2000greenspringassociates.comOwings Mills, United States
Early-stage US companies are invested in by RONA Holdings.
ronaholdings.comCupertino, United States
Venture capital firm
iqt.orgWashington, Dc, United States
Investments are directed toward semiconductors, telecommunications, software, and medical sectors.
samsungventures.comSeoul, South Korea
Growth-stage healthcare companies are invested in by EW Healthcare Partners.
ewhealthcare.comNew York, United States
Sector-agnostic investments in late-stage startups are made by Cross Creek.
crosscreek.vcSalt Lake City, United States
Venture debt is provided globally across multiple sectors.
1980westerntech.comPortola Valley, United States
Premium access

Investor details for IntegenX

The complete investor list, round-by-round participation and investor portfolios require an active premium plan.

  • Complete investor list
  • Round participation
  • Investor portfolios
  • Co-investor network

Verified entity values are shown only after access is granted.

Investments & Acquisitions by IntegenX

IntegenX has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include GenVault Corporation.

Acquisitions
Company NameDescriptionDomainLocationFoundedAcquiredAmount
Biosamples are stabilized, transported, stored, and retrieved by GenVault.
genvault.comCarlsbad, United States2000Jan 2011β€’β€’β€’β€’
Premium access

Complete acquisition details for IntegenX

Acquired stakes, deal sources and the complete acquisition history require an active premium plan.

  • Acquired stakes
  • Deal sources
  • Complete history
  • Exports

Verified entity values are shown only after access is granted.

Timeline of IntegenX

5 dated milestones of IntegenX across 12 years, from founding to its latest funding, stage changes and deals.

  1. Founded IntegenX is founded.
  2. Funding First funding round of $4.5M.
  3. Acquisition Acquires GenVault Corporation.
  4. Funding Latest funding round, Debt – Venture, of $10.0M.
  5. Exit Acquired by Thermo Fisher Scientific.

Competitors of IntegenX

IntegenX has 3 listed competitors in our database, 2 of them funded. They include DDC Paternity Tests, Othram and ANDE.

Company NameDomainFoundedHQ LocationTotal fundingEmployeesDescription
dnacenter.com1995Fairfield, United States
DNA tests and personalized diagnostics are provided for various specialties.
othram.com2018Houston, United States$33.16M22
Genomic services are provided for forensic investigations and research.
ande.com2000Waltham, United States$131.3M49
Rapid DNA systems are provided for forensic identification and diagnostics.
Premium access

Detailed competitors of IntegenX

The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.

  • Full competitor set
  • Operating metrics
  • Benchmarks
  • Competitive positioning

Verified entity values are shown only after access is granted.

Top companies in Genomics & Gene Therapy Platforms

3 companies that operate in the same segment as IntegenX (Genomics & Gene Therapy Platforms) in United States, ranked by their profile score on The Company Check.

CompanyDescriptionFoundedLocationTotal fundingRevenueEmployees
mRNA-based therapeutics for diseases including cancer and infections are developed.
2010Cambridge, Massachusetts, United StatesUSD 2.78 BUSD 1.94 B5,800
Digital sequencing technology for cancer detection is developed.
2012Redwood City, California, United StatesUSD 557.5 MUSD 982.02 M4,867
Circulating tumor DNA is screened for early cancer detection.
2016Menlo Park, California, United StatesUSD 2 BUSD 147.17 M1,141
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track β€” from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • βœ“
    Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • βœ“
    Full access to every database India & global coverage, advanced filters and rich profile details
  • βœ“
    Always-on access from your team account Single premium plan for everything you see on the portal

Related news about Integenx

Premium access

Complete news archive for IntegenX

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about IntegenX

IntegenX was founded in 2006.

IntegenX is headquartered in Pleasanton, United States. It is registered at Pleasanton, California, United States.

IntegenX is a funded company, having raised a total of $92.06M across 9 funding rounds to date. The company's 1st funding round was a Series A of $4.5M, raised on Aug 2006.

IntegenX has 78 employees.

Annual revenue of IntegenX is $22.5B as on Dec 31, 2024.

Founded in 2006 and based in Pleasanton, United States, IntegenX operates in the forensics and law enforcement sector. Advanced fluidics, optics, and biochemistry are integrated into its proprietary platforms to create sample-to-answer products for DNA-based identity testing. As of January 2016, the RapidHIT ID and RapidHIT System, along with supporting reagent kits, are offered for these applications.

IntegenX's top competitors include DDC Paternity Tests, Othram and ANDE.

IntegenX offers RapidHIT ID System and TaqMan Real-Time PCR Assays.

IntegenX has made 1 acquisition, including GenVault Corporation.

IntegenX has 13 investors. Key investors include Thermo Fisher Scientific, Square 1 Bank, HHS, Horizon Tech Finance, and Western Technology Investment.

IntegenX operates through Thermo Fisher Scientific Inc..

Yes. IntegenX was acquired by Thermo Fisher Scientific in March 2018.

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available